Cargando…
Identification of pseudo-immune tolerance for chronic hepatitis B patients: Development and validation of a non-invasive prediction model
BACKGROUND AND AIMS: Patients with chronic hepatitis B (CHB) in the immune tolerant (IT) phase were previously thought to have no or slight inflammation or fibrosis in the liver. In fact, some CHB patients with normal ALT levels still experience liver fibrosis. This study aimed to develop and valida...
Autores principales: | Li, Shuo, Li, Zhiguo, Du, Hongbo, Zao, Xiaobin, Gan, Da’nan, Yang, Xianzhao, Li, Xiaoke, Xing, Yufeng, Ye, Yong’an |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113541/ https://www.ncbi.nlm.nih.gov/pubmed/37089512 http://dx.doi.org/10.3389/fpubh.2023.1137738 |
Ejemplares similares
-
Integrated analysis of single-cell and bulk RNA-sequencing reveals tumor heterogeneity and a signature based on NK cell marker genes for predicting prognosis in hepatocellular carcinoma
por: Li, Shuo, et al.
Publicado: (2023) -
Systematic review: Clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis
por: Yao, Yuhao, et al.
Publicado: (2022) -
Network pharmacology and in vitro experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinoma
por: Cao, Xu, et al.
Publicado: (2022) -
A Non-invasive Model for Predicting Liver Inflammation in Chronic Hepatitis B Patients With Normal Serum Alanine Aminotransferase Levels
por: Li, Xiaoke, et al.
Publicado: (2021) -
The mechanism of TiaoGanYiPi formula for treating chronic hepatitis B by network pharmacology and molecular docking verification
por: Cao, Xu, et al.
Publicado: (2021)